Hyundai

SEOUL, Feb. 4 (UPI) — South Korea’s Hyundai Rotem said Wednesday that it has signed a $220 million contract to supply high-floor light rail vehicles to Edmonton, Canada.

Under the agreement, Hyundai Rotem is scheduled to deliver 32 trainsets, each composed of three cars, to operate through the city center at a maximum speed of 50 mph.

The company noted that the fleet would replace aging rolling stock, with safety and passenger comfort as top priorities.

Because of the city’s harsh winter climate, the trains will feature customized designs that can withstand extreme cold and heavy snowfall.

Hyundai Rotem previossly has sign train deals in Canada.

In 2021, the Hyundai Motor Group subsidiary secured a separate contract to provide trams for Edmonton. Deliveries of those vehicles started last August, according to the company.

In 2005, it also struck an agreement to supply automated people movers for Vancouver International Airport as part of preparations for the 2010 Vancouver Winter Olympic Games.

“We will keep strengthening our relationship to contribute to Canada’s efforts to build environmentally friendly rail infrastructure,” Hyundai Rotem said in a statement. “The country is speeding up the replacement of diesel-powered rail vehicles with electric and hydrogen hybrid trains.”

In addition to rail systems, Hyundai Rotem also operates in the defense sector. It is best known for producing the K2 main battle tank for the South Korean military and overseas customers.

Over the past few years, the defense giant exported 180 K2 tanks to Poland. Last year, it finalized a second major contract to ship another 180 tanks to the European country in a deal valued at about $6.5 billion.

SEOUL, Jan. 27 (UPI) — South Korea’s Hyundai ADM Bio announced plans to launch global clinical trials of its new drug, Penetrium, for rheumatoid arthritis and prostate cancer during a symposium held in Seoul on Tuesday.

Citing promising preclinical results, the biopharmaceutical company said that it aims to begin the clinical tests in the near future.

“In the field of rheumatoid arthritis, we expect to enter clinical trials simultaneously in South Korea and the United States,” Hyundai ADM Bio CEO Cho Won-dong said. “For prostate cancer, we have already received approval from the Korean authorities.”

Dankook University professor Choy Jin-ho, who played a key role in the development of Penetrium, expressed hope that the new-concept drug could bring about a paradigm shift in the fight against multiple diseases, including other types of tumors in addition to prostate cancers.

“A significant portion of anticancer drug resistance is not caused by genetic mutations in cancer cells themselves, but rather by the formation of stroma around them during treatment, which acts like a fortress wall blocking drug penetration,” he said.

Choy said Penetrium was designed to target the “fortress wall,” or the supportive structure around cancer cells, so that drugs could be delivered more effectively.

The symposium brought together experts at home and abroad. Among them were Dr. John Isaacs, professor clinical rheumatology at Newcastle University in the United Kingdom, and Dr. Frederick Millard, a professor of medicine at UC San Diego Health.

Isaacs is one of the leading experts on rheumatoid arthritis, while Millard is known for his contributions to prostate cancer research.

Noting that conventional rheumatoid arthritis treatments often involved immune suppression and significant side effects, Isaacs praised Hyundai ADM Bio’s approach of controlling only the metabolism of pathological cells without suppressing the immune system.

Millard expressed optimism about the new strategy breaking down the protective barriers that shield cancerous cells, instead of targeting them for direct destruction.

The share price of Hyundai ADM Bio jumped 13.56% on the Seoul bourse on Wednesday. Its parent company, Hyundai Bioscience, surged by the daily limit of 30%.